FutureMeds Joins Medpace Prestigious Flagship Site Programme as First Private Site Network

FutureMeds has been recognised as the first private site network to join Medpace’s Flagship Site Programme, due to FutureMeds teams’ demonstrated ‘ability to execute trials with precision and care across a broad range of therapeutic areas.’ 

Site networks are playing a more central role in global research. According to industry data, over two-thirds of sites fail to meet the original patient enrolment for a given trial. More worryingly, up to 50% of sites enrol one or no patients in their studies for various reasons. 

As clinical trials become more complex, with intricate regulatory requirements and a demand for diverse patient populations, the ability to standardise processes and effectively scale operations has become essential. 

Networks help address these challenges by providing pre-qualified infrastructure, coordinated contracting, and local community engagement, reducing site performance variability and improving enrolment outcomes.  

The Flagship Site Programme is Medpace’s leading exclusive initiative, developed to build strategic collaborations with high-performing clinical research sites that consistently deliver exceptional data quality, operational excellence and patient-centric care. 

"Following a thorough evaluation process, FutureMeds has earned its place among the best – demonstrating its ability to execute trials with precision and care across a broad range of therapeutic areas."

— Tonia Koutsoukou, Global Site Relationship Manager, Medpace 

"As part of Flagship Site Programme, FutureMeds will benefit from Medpace’s scientifically-driven approach and deep operational support. Together, we will streamline communication, align on key objectives, and work side by side to deliver faster, more efficient trials, bringing innovative treatments to patients across Europe,"  added Tonia Koutsoukou.

FutureMeds' Certificate of Excellence granted by Medpace

The move reflects a growing shift in the clinical trials industry towards closer collaboration with site networks as global sponsors seek faster, more predictable site performance and broader patient access amid increasing geopolitical and regulatory uncertainty. 

"This recognition further solidifies our reputation as a leader in clinical research, making us an even more attractive partner for sponsors. We’ve enhanced our systems, strengthened our people, and aligned to the needs of sponsors who require both speed and precision.” 

— Cameron Glen, VP of Global Business Development at FutureMeds 

A Strategic Response to Industry Headwinds 

Clinical trials are becoming more complex, with rising expectations for speed, data quality, and patient diversity. At the same time, delays in site activation, inconsistent recruitment, and a shrinking pool of experienced Principal Investigators, combined with a delicate global political climate, have added operational risk for sponsors. 

The European Union’s new Clinical Trials Regulation aims to create a more harmonised regulatory framework, and regional site networks are helping sponsors tap into underutilised patient populations while reducing startup timelines. 

FutureMeds' pan-European footprint and Decentralised solution allow the network to deliver both geographic reach and operational consistency, factors increasingly prized by global drug developers. 

“We’ve performed many studies with Medpace, including large-scale programs that have demonstrated our ability to recruit quickly and consistently. We see even greater potential in oncology, which is now one of our fastest-growing area of focus.” 

— Wojciech Szczepanik, Executive VP of Site Operations  

Raising the Bar on Site–CRO Collaboration 

The Medpace Flagship Site Programme was created to identify and strengthen relationships with high-performing research sites that consistently deliver exceptional data quality, operational excellence and patient-centric care. 

For timely, high-quality outcomes for Sponsors, Medpace meets with participating organisations on a regular basis to discuss potential opportunities, provide feedback on current collaborations, and assess the current study load.  

“This partnership allows both sides to work smarter together,” said Glen. “Sponsors benefit from faster site activation, stronger patient recruitment, and higher confidence in trial delivery.” 

Through this collaboration, FutureMeds and Medpace will align more closely to accelerate trial delivery and improve patient access to new therapies across Europe. 

About Medpace 

Medpace is a scientifically-driven, global, full-service clinical contract research organisation (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective.